Prof Itamar Raz (Hadassah Hebrew University Hospital, Jerusalem, IL) discuss DECLARE-TIMI 58 Trial: SGLT2 call for new guidelines.
1. What is the DECLARE-TIMI 58 trial?
2. What were your latest findings to date?
3. What impact this could have on clinical practice?
4. Can you comment on the latest ESC/EASD guideline and the role of SGLT2 inhibitors?
5. How can physicians personalize therapy according to their patient’s cardio-renal status?
Filmed on site at EASD 2019 by Radcliffe Cardiology